Innovasis HA PEEK Data Registry Reaches Significant Enrollment of 150 Patients

SALT LAKE CITY, May 13, 2019 – The Innovasis, Inc. HA PEEK Data Registry has reached significant enrollment of 150 patients from multiple participating surgeons since the registry was launched in late 2018. This milestone solidifies Innovasis’ commitment to the research and clinical data of their HA Enhanced PEEK technology.  

The HA PEEK Data Registry is a multicenter, observational, quality-assessment repository to track patient outcomes treated with HA PEEK. It allows surgeons to collect outcomes and fusion rates in a secure HIPAA-compliant database that can be accessed on a real-time basis. Currently 8 centers are participating in the registry with the intention to add more throughout the year.

The HA PEEK Data Registry allows me to track my patients and trust my results,” said Dr. Timothy Bassett. “Innovasis’ HA PEEK interbodies provide a quick and more permanent resolution in pain for my patients and the registry is a user-friendly tool to show those results and improvements.”

Advertisement

The data collected in the HA PEEK Data Registry serves as an archive of clinical data on HA PEEK Interbody Fusion Devices. Innovasis offers a complete portfolio of interbody devices compromised of 80% PEEK and 20% integrated hydroxyapatite, providing osteoconductive properties that may improve fusion. For more information on the HA PEEK Data Registry and Innovasis products visit innovasis.com.

About Innovasis, Inc.

Innovasis is a groundbreaking company engaged in the research, development, manufacturing, and marketing of spinal implant devices and related products. Innovasis offers a spinal product line with implants and instruments that address the major pathologies and focus areas of traditional spinal surgery.

Innovasis Media Contact

Hayley Hendrix, 801-261-2236

hhendrix@innovasis.com

Add a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Keep Up to Date with the Most Important News

By pressing the Subscribe button, you confirm that you have read and are agreeing to our Privacy Policy and Terms of Use
Advertisement